688575
vs
S
Shanghai Composite
688575
Over the past 12 months, Shenzhen YHLO Biotech Co Ltd has underperformed Shanghai Composite, delivering a return of -17% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688575 vs Shanghai Composite
Performance Gap
688575 vs Shanghai Composite
Performance By Year
688575 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shenzhen YHLO Biotech Co Ltd
Glance View
In the bustling city of Shenzhen, a beacon of China's rapid technological advancement, YHLO Biotech Co Ltd has emerged as a dynamic player in the healthcare diagnostics industry. Founded in 2008, YHLO Biotech focuses on the development, manufacturing, and distribution of in-vitro diagnostic products. By leveraging cutting-edge immunodiagnostic technologies, the company spearheads innovations in autoimmune disease diagnostics, infectious disease testing, and respiratory pathogen detection. Driven by a commitment to precision and reliability, YHLO Biotech integrates advanced automation solutions and robust biological research to produce diagnostic kits that serve hospitals, laboratories, and research institutions across the globe. YHLO Biotech's business model revolves around an intricate blend of product sales and strategic partnerships. By establishing a diverse portfolio of diagnostic instruments and reagent kits, they cater to both public and private healthcare sectors. The company also engages in collaborations with international diagnostic companies, enhancing its global footprint and broadening market access. Revenue generation at YHLO Biotech is primarily rooted in the sale of these diagnostic solutions, which are consistently updated to meet evolving medical standards and demands. Coupled with their investment in R&D and a rigorous quality control process, YHLO Biotech not only maintains a competitive edge but also fortifies its position as a trusted entity within the medical diagnostics landscape.
